Marinus Preferred Stock Total Equity vs Total Current Liabilities Analysis
MRNS Stock | USD 1.66 0.06 3.75% |
Marinus Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Marinus Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marinus Pharmaceuticals is a good investment. Please check the relationship between Marinus Pharmaceuticals Preferred Stock Total Equity and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.
Preferred Stock Total Equity vs Total Current Liabilities
Preferred Stock Total Equity vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marinus Pharmaceuticals Preferred Stock Total Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Marinus Pharmaceuticals' Preferred Stock Total Equity and Total Current Liabilities is -0.38. Overlapping area represents the amount of variation of Preferred Stock Total Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Marinus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Marinus Pharmaceuticals' Preferred Stock Total Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Preferred Stock Total Equity of Marinus Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Preferred Stock Total Equity i.e., Marinus Pharmaceuticals' Preferred Stock Total Equity and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.38 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Preferred Stock Total Equity
Total Current Liabilities
Total Current Liabilities is an item on Marinus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Marinus Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Marinus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marinus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.At this time, Marinus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 602.7 M in 2024, whereas Tax Provision is likely to drop slightly above 94 K in 2024.
Marinus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Marinus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Marinus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 98.8M | 150.5M | 136.8M | 259.5M | 170.9M | 102.1M | |
Other Current Liab | 4.8M | 8.0M | 21.2M | 46.9M | 22.1M | 23.2M | |
Total Current Liabilities | 8.0M | 10.7M | 40.6M | 54.9M | 40.6M | 42.7M | |
Total Stockholder Equity | 87.8M | 137.2M | 53.5M | 116M | 16.8M | 15.9M | |
Property Plant And Equipment Net | 2.3M | 1.9M | 2.5M | 4.2M | 4.8M | 5.1M | |
Net Debt | (90.5M) | (138.0M) | (82.1M) | (167.9M) | (10.2M) | (10.7M) | |
Retained Earnings | (235.6M) | (311.9M) | (410.7M) | (430.5M) | (571.9M) | (543.3M) | |
Accounts Payable | 2.8M | 2.2M | 3.1M | 6.3M | 4.0M | 2.6M | |
Cash | 90.9M | 138.5M | 122.9M | 240.6M | 120.6M | 88.1M | |
Non Current Assets Total | 4.7M | 10.3M | 13.9M | 19.0M | 5.7M | 7.8M | |
Non Currrent Assets Other | 2.4M | 6.9M | 11.4M | 14.7M | 819.0K | 778.0K | |
Cash And Short Term Investments | 91.7M | 138.5M | 122.9M | 240.6M | 150.3M | 92.1M | |
Common Stock Total Equity | 53K | 87K | 37K | 50K | 57.5K | 35.9K | |
Common Stock Shares Outstanding | 13.6M | 27.3M | 36.7M | 39.1M | 53.7M | 56.4M | |
Liabilities And Stockholders Equity | 98.8M | 150.5M | 136.8M | 259.5M | 170.9M | 102.1M | |
Other Current Assets | 2.5M | 6.3M | 6.1M | 5.4M | 8.7M | 9.2M | |
Other Stockholder Equity | 295.1M | 444.6M | 459.9M | 542.4M | 588.7M | 618.1M | |
Total Liab | 11.1M | 13.3M | 83.4M | 143.5M | 154.1M | 161.9M | |
Property Plant And Equipment Gross | 2.3M | 1.9M | 3.9M | 5.7M | 5.7M | 6.0M | |
Total Current Assets | 94.1M | 140.2M | 122.9M | 240.6M | 165.2M | 94.3M | |
Accumulated Other Comprehensive Income | (96K) | (2K) | 0.0 | (20K) | (23K) | (24.2K) | |
Common Stock | 53K | 87K | 37K | 50K | 55K | 37.9K | |
Property Plant Equipment | 2.3M | 1.9M | 2.5M | 4.2M | 4.9M | 5.1M | |
Net Tangible Assets | 87.8M | 132.7M | 53.5M | 112.0M | 128.8M | 76.0M | |
Retained Earnings Total Equity | (235.6M) | (311.9M) | (410.7M) | (430.5M) | (387.5M) | (368.1M) | |
Short Term Investments | 19.9M | 5.0M | 739K | 1.5M | 29.7M | 31.2M | |
Non Current Liabilities Total | 3.0M | 2.5M | 42.8M | 88.6M | 113.5M | 119.2M | |
Capital Surpluse | 295.1M | 444.6M | 459.9M | 542.4M | 623.8M | 317.7M | |
Net Invested Capital | 59.6M | 132.7M | 40.8M | 71.0M | 89.7M | 81.7M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.